Kodiak Sciences (NASDAQ:KOD) reported that its Phase III DAYBREAK study met primary endpoints for two investigational treatments in treatment-naïve patients with wet age-related macular degeneration, or wet AMD, with both therapies demonstrating statistical equivalence to aflibercept on visual-acuit
What Happened? A number of stocks jumped in the afternoon session after weaker-than-expected U.S. employment data cooled Treasury yields, easing borrowing-co...
What Happened? A number of stocks jumped in the afternoon session after weaker-than-expected U.S. employment data cooled Treasury yields, easing borrowing-co...
What Happened? A number of stocks jumped in the afternoon session after weaker-than-expected U.S. employment data cooled Treasury yields, easing borrowing-co...
What Happened? A number of stocks jumped in the afternoon session after weaker-than-expected U.S. employment data cooled Treasury yields, easing borrowing-co...
Insider doubled down after stock fell 16% over the past year, signaling confidence in the contact lens and surgical care provider's recovery prospects.
What Happened? A number of stocks jumped in the afternoon session after weaker-than-expected U.S. employment data cooled Treasury yields, easing interest rat...
What Happened? A number of stocks jumped in the afternoon session after weaker-than-expected U.S. employment data cooled Treasury yields, easing interest rat...
AST SpaceMobile ships three more BlueBird satellites toward launch amid production gains, but a securities fraud lawsuit, earnings misses, and short interest cloud the stock's outlook.
Gold Royalty (NYSEAMERICAN:GROY) outlined its view that the royalty business model is positioned to benefit from higher gold prices and mining-sector inflation, while highlighting a portfolio it expects to deliver substantial growth in gold-equivalent production through the end of the decade.
Durin
